Search research articles
Contact Us
Filters
Showing results (21-30 of 83) with videos related to
Page
of 9
Sort By:
Journal of Hematology & Oncology
|
October 27, 2015
Complexity of FGFR signalling in metastatic urothelial cancer
Alejo Rodriguez-Vida, Matilde Saggese, Simon Hughes, et al.
Virchows Archiv : an International Journal of Pathology
|
November 28, 2023
Immunohistochemical markers as predictors of prognosis in multifocal prostate cancer
Laura Segalés, Nuria Juanpere, Nerea Gallarín, et al.
BJU International
|
July 13, 2020
Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study)
Alejo Rodriguez-Vida, Aristotelis Bamias, Emilio Esteban, et al.
Biorxiv : the Preprint Server for Biology
|
March 10, 2025
Tumor B cell infiltration in platinum-treated advanced urothelial carcinoma
Konrad Stawiski, Júlia Perera-Bel, Alejo Rodriguez-Vida, et al.
Molecular Oncology
|
June 2, 2026
Tumor B-cell infiltration in platinum-treated advanced muscle-invasive urothelial carcinoma
Konrad Stawiski, Júlia Perera-Bel, Alejo Rodriguez-Vida, et al.
Molecular Cancer Research : MCR
|
June 5, 2019
Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
Anna Hernández-Prat, Alejo Rodriguez-Vida, Nuria Juanpere-Rodero, et al.
Scientific Reports
|
September 15, 2023
The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer
Lilian Marie Boll, Júlia Perera-Bel, Alejo Rodriguez-Vida, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
April 10, 2025
Prognostic Value of PARP1 and PARP2 Copy Number Alterations in Prostate Cancer
Laura Segalés, Joaquim Bellmunt, Júlia Perera-Bel, et al.
Frontiers in Oncology
|
June 7, 2021
Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study
Nicolas Epaillard, Pauline Parent, Yohann Loriot, et al.
European Urology Oncology
|
November 5, 2025
Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial
Joan Carles, Bertrand Tombal, Maha Hussain, et al.
Page
of 9
Search research articles
Search
Showing results (21-30 of 83) with videos related to
Sort By:
Page
of 9
Journal of Hematology & Oncology
|
October 27, 2015
Complexity of FGFR signalling in metastatic urothelial cancer
Alejo Rodriguez-Vida, Matilde Saggese, Simon Hughes, et al.
Virchows Archiv : an International Journal of Pathology
|
November 28, 2023
Immunohistochemical markers as predictors of prognosis in multifocal prostate cancer
Laura Segalés, Nuria Juanpere, Nerea Gallarín, et al.
BJU International
|
July 13, 2020
Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study)
Alejo Rodriguez-Vida, Aristotelis Bamias, Emilio Esteban, et al.
Biorxiv : the Preprint Server for Biology
|
March 10, 2025
Tumor B cell infiltration in platinum-treated advanced urothelial carcinoma
Konrad Stawiski, Júlia Perera-Bel, Alejo Rodriguez-Vida, et al.
Molecular Oncology
|
June 2, 2026
Tumor B-cell infiltration in platinum-treated advanced muscle-invasive urothelial carcinoma
Konrad Stawiski, Júlia Perera-Bel, Alejo Rodriguez-Vida, et al.
Molecular Cancer Research : MCR
|
June 5, 2019
Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
Anna Hernández-Prat, Alejo Rodriguez-Vida, Nuria Juanpere-Rodero, et al.
Scientific Reports
|
September 15, 2023
The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer
Lilian Marie Boll, Júlia Perera-Bel, Alejo Rodriguez-Vida, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
April 10, 2025
Prognostic Value of PARP1 and PARP2 Copy Number Alterations in Prostate Cancer
Laura Segalés, Joaquim Bellmunt, Júlia Perera-Bel, et al.
Frontiers in Oncology
|
June 7, 2021
Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study
Nicolas Epaillard, Pauline Parent, Yohann Loriot, et al.
European Urology Oncology
|
November 5, 2025
Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial
Joan Carles, Bertrand Tombal, Maha Hussain, et al.
Page
of 9